Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorMiravitlles Fernández, Marc
dc.contributor.authorGonzález-Torralba, Fernando
dc.contributor.authorRepresas-Represas, Cristina
dc.contributor.authorPomares, Xavier
dc.contributor.authorMárquez-Martín, Eduardo
dc.contributor.authorGonzález, Cruz
dc.contributor.authorBarrecheguren Fernández, Miriam
dc.date.accessioned2022-10-06T07:33:05Z
dc.date.available2022-10-06T07:33:05Z
dc.date.issued2022-07-12
dc.identifier.citationMiravitlles M, González-Torralba F, Represas-Represas C, Pomares X, Márquez-Martín E, González C, et al. Pulmonologists’ Opinion on the Use of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease Patients in Spain: A Cross-Sectional Survey. Int J Chron Obstruct Pulmon Dis. 2022 Jul 12;17:1577–87.
dc.identifier.issn1178-2005
dc.identifier.urihttps://hdl.handle.net/11351/8259
dc.descriptionCOPD; Eosinophils; Inhaled corticosteroids
dc.description.abstractIntroduction: Identifying the variables that guide decision-making in relation to the use of inhaled corticosteroids (ICS) can contribute to the appropriate use of these drugs. The objective of this study was to identify the clinical variables that physicians consider most relevant for prescribing or withdrawing ICS in COPD. Methods: A cross-sectional survey was conducted in Spain from November 2020 to May 2021. Therapeutic decisions on the use of ICS in 11 hypothetical COPD patient profiles were collected using an online survey answered by specialists with experience in the management of patients with COPD. Mixed-effects logistic regression was used to analyze the impact of patients’ characteristics in the therapeutic decision for prescribing ICS or proceeding to its withdrawal. Results: A total of 74 pulmonologists agreed to collaborate in the survey and answered the questionnaire. The results showed great variability, with only 2 profiles achieving consensus for starting or withdrawing the treatment. The frequency and severity of exacerbations influenced the decision to prescribe ICS in a dose-response fashion (1 exacerbation odds ratio (OR) = 1.86, 95% confidence interval (CI) 1.02 to 3.43, two exacerbations OR = 11.6, 95% CI: 4.47 to 30.2 and three OR = 123, 95% CI: 25 to 601). Similarly, increasing blood eosinophils and history of asthma were associated with ICS use. On the other hand, pneumonia reduced the probability of initiating treatment with ICS (OR = 0.54 [0.29 to 0.98]). Lung function and dyspnea degree did not influence the clinician’s therapeutic decision. The results for withdrawal of ICS were similar but in the opposite direction. Conclusion: In accordance with guidelines, exacerbations, blood eosinophils and history of asthma or pneumonia are the factors considered by pulmonologist for the indication or withdrawal of ICS. However, the agreement in prescription or withdrawal of ICS when confronted with hypothetical cases is very low, suggesting a great variability in clinical practice.
dc.language.isoeng
dc.publisherDove Medical Press
dc.relation.ispartofseriesInternational Journal of Chronic Obstructive Pulmonary Disease;17
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectPulmons - Malalties obstructives - Tractament
dc.subjectCorticosteroides - Efectes secundaris
dc.subjectEnquestes
dc.subject.meshPulmonary Disease, Chronic Obstructive
dc.subject.meshSurveys and Questionnaires
dc.subject.meshAdrenal Cortex Hormones
dc.subject.mesh/adverse effects
dc.titlePulmonologists’ Opinion on the Use of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease Patients in Spain: A Cross-Sectional Survey
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.2147/COPD.S369118
dc.subject.decsenfermedad pulmonar obstructiva crónica
dc.subject.decsencuestas y cuestionarios
dc.subject.decshormonas de la corteza suprarrenal
dc.subject.decs/efectos adversos
dc.relation.publishversionhttps://doi.org/10.2147/COPD.S369118
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Miravitlles M] Servei de Pneumologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. CIBER de Enfermedades Respiratorias (CIBERES), ISCIII, Madrid, Spain. [González-Torralba F] Pneumology Department, Hospital Universitario del Tajo, Aranjuez, Spain. [Represas-Represas C] Pneumology Department, Hospital Álvaro Cunqueiro, Vigo, Spain. [Pomares X] CIBER de Enfermedades Respiratorias (CIBERES), ISCIII, Madrid, Spain. Pneumology Department, Corporació Sanitària Parc Taulí, Sabadell, Spain. [Márquez-Martín E] CIBER de Enfermedades Respiratorias (CIBERES), ISCIII, Madrid, Spain. Medical-Surgical Unit for Respiratory Diseases, Hospital Universitario Virgen del Rocío, Sevilla, Spain. [González C] Pneumology Department, Hospital Clínico de Valencia, Valencia, Spain. [Barrecheguren M] Servei de Pneumologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain
dc.identifier.pmid35855745
dc.identifier.wos000828314400001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record